Equillium reports inducement grant under nasdaq listing rule 5635(c)(4)

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on may 31, 2024, the compensation committee of equillium's board of directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under equillium's 2024 inducement plan. the compensation committee appr.
EQ Ratings Summary
EQ Quant Ranking